| Literature DB >> 32397389 |
Ramya Selvaraj1, Nilesh J Vasa1, S M Shiva Nagendra2, Boris Mizaikoff3.
Abstract
Human exhaled breath consists of more than 3000 volatile organic compounds, many of which are relevant biomarkers for various diseases. Although gas chromatography has been the gold standard for volatile organic compound (VOC) detection in exhaled breath, recent developments in mid-infrared (MIR) laser spectroscopy have led to the promise of compact point-of-care (POC) optical instruments enabling even single breath diagnostics. In this review, we discuss the evolution of MIR sensing technologies with a special focus on photoacoustic spectroscopy, and its application in exhaled breath biomarker detection. While mid-infrared point-of-care instrumentation promises high sensitivity and inherent molecular selectivity, the lack of standardization of the various techniques has to be overcome for translating these techniques into more widespread real-time clinical use.Entities:
Keywords: MIR; QCL; biomarkers; exhaled breath analysis; infrared lasers; mid-infrared; non-invasive diagnostics; photoacoustic spectroscopy; point-of-care (POC); quantum cascade lasers
Mesh:
Substances:
Year: 2020 PMID: 32397389 PMCID: PMC7249025 DOI: 10.3390/molecules25092227
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(a) Pathways for volatile organic compounds (VOCs) in the human body; (b) Schematic diagram of the formation of acetoacetate, beta-hydroxybutyrate, and acetone, which takes place in the mitochondrial matrix of the liver.
List of biomarkers and their relation to potential disease states.
| S. No | Disease | Potential Source of Biomarker | Biomarker | Concentration (diseased) | Concentration (healthy) | Reference |
|---|---|---|---|---|---|---|
| 1 | Diabetes | Oxidation of non-osterified fatty acids | Acetone (CH3)2CO | T1D: >2.2 ppm, typically >10 ppm | 0.39 to 0.85 ppm | [ |
| 2 | Colorectal cancer | (1) High lipid, low-fat diet; (2) increased presence of bile salts; | Methane (CH4) | 8 to 50 ppm | 3 to 8 ppm | [ |
| 3 | Non-small cell lung cancer (NSCLC) | Oxidative stress | Interleukin-6 | 9.3 to 9.9 pg/mL | 3.3 to 3.7 pg/mL | [ |
| 4 | Blood cholesterol | Mevalonate pathway of lipid (cholesterol) metabolism | Isoprene | - | 3.5 to 10.5 nmol/L. | [ |
| 5 | Myocardial infarction | Lipid peroxidation, leading to the pathogenesis of tissue damage | Pentane (C5H12) | - | 0.3 to 0.8 nmol/L | [ |
| 6 | Obstructive sleep apnea | Oxidative stress | Interleukin-6 (IL-6), 8-isoprostane | 8.4 to 9.0 pg/mL | 1.5 to 1.7 pg/mL | [ |
| 7 | Smoking | Carbon Monoxide (CO) | 2 to 20 ppm (smokers) | 0.4 to 0.8 ppm (non-smokers) | [ | |
| 8 | Renal failure, oral cavity disease | Lipid peroxidation | Ammonia (NH3) | 0.25 to 2.9 ppm | [ | |
| 9 | Scleroderma, cystic fibrosis | Ethane (C2H6) | 0 to 12 ppb | [ | ||
| 10 | Asthma, acute lung injury, inflammatory lung diseases, lung infection, lung cancer, rhinitis | Nitric oxide synthase | Nitric Oxide (NO) | <35 ppb | [ |
Figure 2Simplified schematic of (a) mid-infrared (MIR) absorption spectroscopy, (b) cavity ring-down spectroscopy (CRDS), and (c) multi-pass spectroscopy (MUPASS). (DAQ: Data Acquisition system).
Figure 3(a) Substrate-integrated hollow waveguide (iHWG) assembly with a yin-yang structure; (b) Schematic of the iHWG sensor system [62]. (FTIR: Fourier Transform Infrared Spectrometer; MCT: Mercury-Cadmium-Telluride).
Spectral fingerprints, laser techniques employed, and detection limit of select few biomarkers.
| S. No | Biomarker | Technique | Light Source | Wavelength (µm) | Detection Limit | Reference |
|---|---|---|---|---|---|---|
| 1 | Nitric Oxide (NO) | CEAS | QCL | 5.262961 | 5 ppb | [ |
| ICOS | QCL | 5.22 | 0.4 ppb | [ | ||
| CALOS | CO laser | 5 | 7 ppt | [ | ||
| TDLAS | IV–VI laser | 5.2 | 1.5 ppb | [ | ||
| MP absorption spectroscopy | QCL | 5.2630 | 0.3 ppb | [ | ||
| CEAS | QCL | 5.2630 | 30 ppb | [ | ||
| 2 | Carbonyl Sulphide (OCS) | CALOS | CO laser | 5 | 438 ± 4.4 ppt | [ |
| CEAS | QCL | 4.8716 | 0.9 ppb | [ | ||
| 3 | Ethane (C2H6) | CALOS | ECDL 800 nm an d Nd-YAG 1064 nm with PPLN | 3.34 | 1–100 ppb | [ |
| CEAS | Tunable laser system | 3.3481 | 0.3 ppb | [ | ||
| TDLAS | ICL | 3.34 | 1.2 ppb | [ | ||
| 4 | Methane (CH4) | HCF | 3.4 | ppm | [ | |
| MP absorption spectroscopy | QCL | 7.874 | 1 ppb | [ | ||
| 5 | Acetone (CO(CH3)2) | WMS | DFB-ICL | 3.367 | 0.58 ppm (1 s) 0.12 ppm (60 s) | [ |
| WMS-MP-Broadband DAS | EC-QCL | ~7.4 | 15 ppbv (<10 s) | [ | ||
| CEAS | QCL | 8.22 | 0.51 ppm | [ | ||
| 6 | Ammonia (NH3) | MP absorption spectroscopy | QCL | 10.341 | 0.2 ppb | [ |
| WMS-MP | QCL | 9.062 | 7 ppbv | [ | ||
| Pulsed CRDS | QCL | 10.309 | 50 ppb | [ | ||
| 7 | Carbon Monoxide (CO) | TDLAS-MP | ICL | 4.69 | 9 ± 5 ppbv | [ |
| 8 | Ethylene (C2H4) | MP absorption spectroscopy | QCL | 10.416 | 0.5 ppb | [ |
| CALOS | CO2 laser | 10 | [ | |||
| 9 | Formaldehyde (HCHO) | MP absorption spectroscopy | QCL | 5.665 | 0.15 ppb | [ |
CEAS: cavity-enhanced absorption spectroscopy, ICOS: integrated cavity output spectroscopy, CALOS: cavity leak-out absorption spectroscopy, TDLAS: tunable diode laser absorption spectroscopy, MP: multipass, WMS: wavelength modulation spectroscopy, DAS: direct absorption spectroscopy, CRDS: cavity ring-down spectroscopy, QCL: quantum cascade laser, ECDL: external cavity diode laser, DFB-ICL: distributed feedback-intracavity laser, HCF: hollow core fibre, PPLN: periodically poled lithium niobate.
Figure 4(a) General schematic of the photoacoustic (PA) signal generation process; (b) general schematic of the PA sensor architecture.
Figure 5General quartz-enhanced photoacoustic spectroscopy (QEPAS) sensor architecture.
Figure 6Broadband absorption spectra for methane.